TBPH logo

Theravance Biopharma, Inc.


TBPH: Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).


Show TBPH Financials

Consumer Interest
SEC Filings

Recent trades of TBPH by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by TBPH's directors and management

Government lobbying spending instances

  • $40,000 Nov 02, 2021 Issue: Health Issues
  • $40,000 Jul 20, 2021 Issue: Health Issues
  • $30,000 Jul 19, 2021 Issue: Health Issues
  • $30,000 Apr 14, 2021 Issue: Health Issues
  • $20,000 Jan 21, 2021 Issue: Health Issues
  • $20,000 Oct 07, 2020 Issue: Health Issues
U.S. Patents

New patents grants

Quiver Logo

No new patents for this ticker

U.S. Patents Dashboard
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of TBPH in WallStreetBets Daily Discussion


Recent insights relating to TBPH

CNBC Recommendations

Recent picks made for TBPH stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in TBPH

Corporate Flights

Flights by private jets registered to TBPH